Deep Vein Thrombosis Disease Research Articles

Diagnostic value of serum pentraxin-3 in deep vein thrombosis disease

Aim: We investigated the diagnostic value of Pentraxin 3 (PTX-3), a marker that increases in vascular and inflammatory pathologies, in patients admitted to hospital with deep vein thrombosis clinic. Materials and Methods: 44 patients admitted to the a tertiary medical faculty hospital and a tertiary training and research hospital, with suspect of deep vein thrombosis included in our study. Patients confirmed to have DVT by doppler ultrasonography named as DVT(+) group, and patients not confirmed to have DVT by doppler ultrasonography named as DVT (-). PTX-3 levels determined in blood samples and compared between these groups. Results: Median levels of D-dimer in DVT(+) group was 3.92 μg/ml (1.57- 6.05), and in DVT (-) group was 1.47 μg/ml (0.97-2.37), and a statistically significant difference was found between these groups (p<0.05). Median levels of Pentraxin-3 in DVT(+) group was 0.42 (0.36-0.49) μg/ml, and in DVT(-) group 0.40 (0.37-0.49) μg/ml, and there was no significant difference found between these groups (p˃0.05). Conclusion: According to our study, PTX-3 is not a suitable diagnostic marker for the diagnosis of deep vein thrombosis. We think that the value of PTX-3 in the diagnosis of deep vein thrombosis now need to be confirmed with broader, controlled studies.

The treatment effect of rivaroxaban on clot characteristics in patients who present acutely with first time deep vein thrombosis.

The acute vascular disease deep vein thrombosis (DVT) requires oral anticoagulants to prevent progression. Monitoring therapeutic efficacy of direct oral anticoagulants (DOAC), including rivaroxaban, is problematic as no reliable test is available. Advances in rheometry have led to the development of a functional coagulation biomarker using Gel Point (GP) analysis which assesses clot structure formation. The biomarker measures incipient clot formation time (TGP) and quantifies fibrin clot structure in terms of fractal dimension (df). This study aimed to investigate clot structure formation in first time DVT and the effect of rivaroxaban treatment. This prospective observational cohort study measured the GP and standard laboratory markers at three sample points: pre-treatment and at 20 and 60 days following 15 mg BD and 20 mg OD rivaroxaban respectively. Forty DVT patients (mean age 64 years [SD±14.8]; 23 males, 17 female) were recruited. The results show that DVT vs non-DVT patients did not have a significantly different GP profile (df: 1.72±0.06 vs 1.70±0.06 and TGP: 267±68 sec vs 262±73 sec) with both within the defined healthy index. In addition, rivaroxaban therapy increased TGP to 392 s (±135 s) after 20 days, and subsequently increased to 395 s (±194 s) at 60 days but did not significantly increase df (from 1.69±0.05 to 1.71±0.06). The results indicate in this cohort of DVT patients there was no underlying hypercoagulable effect as determined by gel point analysis. Furthermore, the anticoagulant effect of rivaroxaban prolonged clotting, suggesting a protective effect against clot formation, without significantly reducing clot microstructural properties.

Evaluating the Prophylaxis of the Risk of Deep Vein ThrombosisU sing Business Intelligence

Deep Vein Thrombosis (DVT) consists in the formation of a blood clot within the deep veins of the lower limbs. This study explores the data and information collected from the Electronic Health Record of a Health Care Institution. Several concepts such as Data Warehouse, Extract-Transform-Load and Business Intelligence were applied and the use of these technological systems was aimed at obtaining indicators that provide a comprehensive overview from the data collected and assist in decision making. Of all the patients analysed, 11,042 did not obtain any type of prophylaxis, 4508 received pharmacological prophylaxis with low molecular weight heparin (LMWH), 1260 got mechanical prophylaxis and 1119 had to contact the Haematology department. The results achieved allow building a system able to identify low use of prophylaxis and the need to alert health professionals to the importance of these measures in prevention of the DVT disease.